1,4-Bis((3,5-dichloropyridin-2-yl)oxy)benzene

Catalog No. :
ACTIER473
CAS No. :
76150-91-9
Molecular Formula :
C16H8Cl4N2O2
Molecular Weight :
402.06

IUPAC Name:1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene

1,4-Bis((3,5-dichloropyridin-2-yl)oxy)benzene structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$97.00Login to see priceInquiryInquiry
1g97%$317.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1,4-Bis((3,5-dichloropyridin-2-yl)oxy)benzene
IUPAC Name1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene
Molecular FormulaC16H8Cl4N2O2
Molecular Weight402.06
SMILESClC1=CN=C(OC2=CC=C(OC3=NC=C(Cl)C=C3Cl)C=C2)C(Cl)=C1
InChI KeyBAFKRPOFIYPKBQ-UHFFFAOYSA-N
Synonymtcpobop | 76150-91-9 | 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene | 1,4-bis((3,5-dichloropyridin-2-yl)oxy)benzene | 1,4-BDPOB | 1,4-Bis(2-(3,5-dichloropyridyloxy))benzene | Pyridine,2,2'-[1,4-phenylenebis(oxy)]bis[3,5-dichloro- | 3,5-dichloro-2-[4-(3,5-dichloropyridin-
CAS No.76150-91-9
PubChem CID5382

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319
Precautionary Statement(s)
P264-P280-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362

Synthetic Route by SureRoute

1. ACTIER473 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACEUIF127 route compound structure diagram
    ACEUIF127823-56-3 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTIER473 route product structure diagram
    ACTIER47376150-91-9
Inquiry

2. ACTIER473 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACHWNA125 route compound structure diagram
    ACHWNA12516063-70-0 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTIER473 route product structure diagram
    ACTIER47376150-91-9
Inquiry

Comments (0)